Neutrogena®, Aveeno®, and Regaine® Present New Scientific Evidence Demonstrating How Science-Backed Ingredients Support Healthy Skin and Hair
Regaine’s post-hoc trial analysis found greater hair regrowth among younger men and those with earlier-stage hair loss.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Research shared at the 35th European Academy of Dermatology and Venereology (EADV) Congress highlights the benefits of multifunctional sunscreens, colloidal oat formulations addressing acne, hyperpigmentation, eczema, UV-related skin damage, and the impact of
New Neutrogena science showcased at EADV 2026 in
Abstracts presented will share new evidence demonstrating how science-backed ingredients including niacinamide, trehalose, colloidal oat and
The findings reinforce a growing body of evidence showing that innovative formulations can deliver benefits beyond traditional expectations by helping protect and strengthen the skin barrier, improve visible skin concerns, and support hair regrowth.
New Research Advances Understanding of Skin Health, Skin Barrier Function and Hair Regrowth
Consumers increasingly seek effective, science-backed solutions that address multiple concerns while fitting seamlessly into daily self-care routines. Research from Neutrogena®, Aveeno® and Regaine® demonstrates how targeted ingredients can provide measurable benefits for skin and hair health while supporting confidence and overall well-being.
"Consumers consistently tell us that healthy skin and healthy hair can have a meaningful impact on their confidence and quality of life," said Kate Stockman, Vice President and Head of EMEA Research & Development at Kenvue. "The research we are presenting at EADV advances our understanding of how ingredients such as niacinamide, colloidal oat and
Neutrogena® Research: Multifunctional Sunscreens Deliver Benefits Beyond UV Protection
Multifunctional sunscreen helps manage oily skin and reduce visible acne-related signs
Consumers are increasingly seeking sunscreens that deliver cosmetic and skin health benefits beyond UV protection. New researchi on Neutrogena® Ultra Sheer Invisible Fluid Sunscreen Oil Control 50+ demonstrates how a broad-spectrum sunscreen formulated with
In two small multi-ethnic Brazilian populations with acne-prone and oily skin, researchers observed:
-
A
56% reduction in visible redness after 28 days -
A
46% reduction in acne-related hyperpigmentation -
Up to a
12% reduction in skin oiliness -
A
10% reduction in visible shine -
A
13% increase in skin hydration -
High consumer satisfaction, with
90% reporting less skin oiliness and78% reporting reduced acne marks
These findings demonstrate how multifunctional sunscreen formulations may help support the appearance of clearer, more balanced skin while protecting against UV exposure.
Niacinamide-containing sunscreen improves hydration and helps visibly reduce sunspots
A second studyii evaluated Neutrogena® Ultra Sheer Invisible Fluid Sunscreen Hydration Fluid 50, formulated with
Researchers found that regular use was associated with:
-
A
22% improvement in skin hydration - Maintenance of skin barrier integrity
- Significant improvements in skin tone uniformity and radiance
- Reductions in visible facial spot size associated with hyperpigmentation
After 28 days of use, more than
Aveeno® Research: Colloidal Oat Supports Skin Barrier Health, Recovery and Eczema Care
Colloidal oat formulation supports skin recovery following UV-related damage
Oat and its concentrated components (avena sativa) have long been recognized for their skin-soothing properties. New researchiii further demonstrates how colloidal oat can support skin barrier function and recovery following UV exposure.
Preclinical and clinical studies evaluating formulations containing the Aveeno® brand’s proprietary Triple Oat Complex found:
- Increased production of key skin barrier proteins, including filaggrin and loricrin
- Preservation of these proteins following UV exposure
- Faster skin recovery following application
- Improved hydration and increased ceramide production
Together, these findings reinforce the important role of colloidal oat in supporting healthy, resilient skin.
Dermatologists report benefits of colloidal oat-based emollients alongside topical corticosteroids for eczema
An international surveyiv of 178 dermatologists and pediatric clinicians across
Among respondents:
-
87.6% reported frequently recommending a specific colloidal oat-based emollient alongside topical corticosteroids -
92.7% reported observing steroid-sparing or steroid-optimization effects - Clinicians reported benefits related to skin barrier support, hydration and reduced treatment-related concerns
The findings highlight the perceived value of colloidal oat-based emollients as a complementary component of eczema care.
Regaine® Research: Earlier Use of
New analysisv suggests earlier intervention may improve hair regrowth outcomes
Androgenetic alopecia, the most common form of hair loss in men, affects an estimated
In a post-hoc analysis of a Phase III clinical trial, researchers assessed changes in non-vellus hair count after 16 weeks of treatment with Regaine®
Key findings included:
- Men aged 20 to 30 years experienced an average increase of 26.25 hairs from baseline after 16 weeks, compared with 19.93 hairs among men older than 30 years.
- Men with Type III hair loss experienced an average increase of 23.06 hairs, compared with 18.70 hairs among men with more advanced Type IV and Type V hair loss.
- Statistically significant improvements in hair regrowth versus placebo were observed across all hair loss classifications (p<0.002).
The analysis concluded that while
Additional Research and Scientific Exchange at EADV 2026
Additional new studies will further reinforce the research of Neutrogena®, Aveeno®, and Regaine® at EADV 2026. Neutrogena® will also sponsor an industry session entitled “Raising the Bar-rier: New Hydration Evidence in Compromised Skin” including industry experts Ted Lain MD, MBA, FAAD, Patrica Farris MD, FAAD, and Kenvue Head of Medical Affairs North America, Skin Health & Baby, Asha Patel Shah MD, MBA, FAAD.
For more information about the research being presented by Neutrogena®, Aveeno®, and Regaine® at the 35th EADV Congress, please contact the media representatives below.
*Neutrogena®, Aveeno®, and Regaine® are brands of Kenvue Brands LLC, a subsidiary of Kenvue Inc.
References |
|
|
|
i Rennó I, Felix D, Satake C, et al. Clinical Evidence of Improved Post Inflammatory Skin Changes and Skin Oiliness with Continuous Use of a Facial Sunscreen Containing |
|
ii Rennó I, Felix D, Moreira G, et al. Additional Therapeutic Benefits of a Sunscreen with |
|
iii Edison BL, Besingi R, Parsa R, et al. Pre-Clinical and Clinical Efficacy of an Oat-containing Lotion Demonstrated Increased Protein, Ceramide, Skin Resiliency and Speed of Healing the Skin Barrier. Presented at: 35th EADV Congress; September 30-October 3, 2026; |
|
iv Peer A, Ahmad AHH, Lisante TA, Pringle L. Clinician-Reported Perceptions of a Colloidal Oat-Based Emollient Used with Topical Corticosteroids in Eczema: Results of a Multinational SERMO Survey. Presented at: 35 EADV Congress; September 30-October 3, 2026; |
|
v Waide RJ, McGuire JA, LaTerra P, Shah AP. Early Intervention of |
|
View source version on businesswire.com: https://www.businesswire.com/news/home/20260930489298/en/
Media Contacts
EMEA Local Media Contact:
Natalie McCabe
nbuhl@kenvue.com
Global R&D Media Relations:
Meghan Harding
MHardin1@kenvue.com
Source: Kenvue